Thank you for Subscribing to Life Science Review Weekly Brief
Emerald Health Pharmaceuticals has added neuroscience specialist and innovator Eduardo Candelario-Jalil, PhD, to its Scientific Advisory Board.
FREMONT, CA: Emerald Health Pharmaceuticals Inc., a clinical-stage biotechnology firm building a new class of medicine to cure diseases with unmet medical requirements, has appointed neuroscience specialist and innovator Eduardo Candelario-Jalil, PhD, to its Scientific Advisory Board.
"We are honored to have Dr. Candelario-Jalil join our Scientific Advisory Board as we advance our research and clinical programs," said Eduardo Mu±oz, MD, PhD, Chief Scientific Officer of EHP. "His expertise and innovative work in neuroinflammatory mechanisms adds greatly to our outstanding team of world-class scientific experts, which includes Professor Giovanni Appendino, PhD, a key opinion leader in chemistry, and Rao Movva, PhD, a Novartis Distinguished Scientist."
Jim DeMesa, MD, MBA, EHPs President, and CEO added, "The addition of Dr. Candelario-Jalil will further expand and strengthen our ability to guide the development of our proprietary molecules with unique capabilities that can potentially modify and reverse disease progression in patients suffering from devastating neurodegenerative and autoimmune diseases.
We look forward to his contributions as we continue to advance our learning and development efforts to more powerfully affect the pathways of these challenging diseases to achieve better therapeutic outcomes."
In addition to his contribution to the EHP Scientific Advisory Board, Dr. Candelario-Jalils has helped conduct preclinical studies in his laboratories at the University of Florida connected to using the Company's technology for the potential treatment of stroke.
Emerald Health Pharmaceuticals is working on cannabinoid-derived product candidates to treat CNS, autoimmune, and other diseases. The Company owns two families of proprietary new chemical entities deduced from synthetic cannabidiol (CBD) and cannabigerol (CBG), which it has altered using rational drug design to impact verified receptors and pathways relevant to targeted disease. EHP-101, the Company's first drug product candidate, has entered Phase 2 clinical trials to treat systemic sclerosis, a severe condition of scleroderma, and multiple sclerosis. EHP-102, its second product candidate, is in preclinical development and aims to cure Parkinson's and Huntington's disease.